sarepta duchenne muscular dystrophy

News

FDA, Sarepta Therapeutics

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an unrelated drug.

· 2d · on MSN

Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths

· 2h

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys

Investor's Business Daily on MSN48m

Sarepta Topples, Again, After Refusing The FDA's Request To Pull Elevidys

Sarepta stock took another dive Monday after the biotech company refused the FDA's request to voluntarily stop all shipments ...

BioSpace2h

Sarepta Stands Ground Against HHS Request to Stop Elevidys Shipments

In light of recent patient deaths, the FDA has also revoked its platform designation for Sarepta’s AAVrh74 technology. The ...

pharmaphorum5h

Sarepta resists as FDA seeks pause on Elevidys use

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

20mon MSN

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino’s, Cleveland-Cliffs, Pinterest, and More

Sarepta says it will continue to ship Elevidys despite FDA requests that it stop shipments of the Duchenne muscular dystrophy gene therapy, while Verizon tops earnings expectation and raises 2025 ...

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

STAT2dOpinion

We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results